Cresset Asset Management LLC Sells 33,523 Shares of Genmab A/S (NASDAQ:GMAB)

Cresset Asset Management LLC decreased its position in shares of Genmab A/S (NASDAQ:GMAB) by 56.6% during the 4th quarter, Holdings Channel reports. The fund owned 25,752 shares of the company’s stock after selling 33,523 shares during the quarter. Cresset Asset Management LLC’s holdings in Genmab A/S were worth $537,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in Genmab A/S by 7.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock valued at $40,199,000 after buying an additional 139,722 shares in the last quarter. First Trust Advisors LP boosted its holdings in Genmab A/S by 18.0% during the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock worth $34,316,000 after purchasing an additional 251,241 shares during the last quarter. Brandywine Global Investment Management LLC acquired a new position in Genmab A/S during the fourth quarter worth $33,804,000. Marshall Wace LLP boosted its holdings in Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock worth $23,422,000 after purchasing an additional 694,243 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Genmab A/S by 18.8% during the fourth quarter. Northern Trust Corp now owns 599,381 shares of the company’s stock worth $12,509,000 after purchasing an additional 94,858 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

GMAB has been the subject of several recent research reports. Sanford C. Bernstein cut shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. Truist Financial reduced their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $39.17.

Genmab A/S Trading Down 1.2%

Shares of Genmab A/S stock opened at $19.08 on Thursday. The firm has a market capitalization of $12.23 billion, a PE ratio of 10.97, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04. The firm’s 50 day moving average is $19.80 and its 200 day moving average is $20.81. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.41.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. The company had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.